CAMBRIDGE, Mass. — MEDIPOST Inc. said its parent company, MEDIPOST Co. Ltd., has closed $140 million in funding to support late-stage clinical development and accelerate a planned Phase III clinical trial in the United States in 2026.
The funding round was led by Skylake Equity Partners and Crescendo Equity Partners, with participation from a leading Korean growth equity fund. MEDIPOST said the investment was completed at the parent-company level and will be used to advance development of its investigational mesenchymal stem cell therapy for the treatment of symptomatic cartilage defects in patients with knee osteoarthritis.
The company said the capital will support scientific and operational expansion, infrastructure development, and the scaling of manufacturing processes as it prepares for Phase III evaluation in the U.S.
“The funding from Korea’s top growth equity funds fuels MEDIPOST’s global expansion as we prepare to advance into Phase III clinical evaluation in the U.S., with trial initiation anticipated in early 2026,” said Edward Ahn, Ph.D., chief executive officer of MEDIPOST Inc. “It allows us to move into late-stage development while continuing to build the clinical, operational and manufacturing foundation needed to bring scalable, off-the-shelf regenerative therapies closer to patients.”
MEDIPOST’s therapeutic approach is based on allogeneic, umbilical cord blood–derived stem cells, which the company said offer advantages including immune tolerance, biologically young cells, and scalable manufacturing. The company views the platform as part of the broader advancement of regenerative medicine for inflammation-driven degenerative diseases.
“MEDIPOST Inc. has demonstrated a disciplined approach to regenerative medicine development, grounded in strong science and clinical rigor,” said Kevin Lee, Ph.D., managing partner and chief executive officer of Crescendo Equity Partners. “We are pleased to support the company as it continues to invest in its platform and prepare for the next phase of clinical development.”
Ahn said the financing represents a key milestone for the company’s U.S. strategy and long-term growth. “Our mission is to develop regenerative therapies that are accessible, scalable and grounded in strong science and clinical rigor,” he said. “This is an important milestone in advancing our programs in the U.S. and strengthens the foundation for continued clinical and operational growth.”
